Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.

BACKGROUND The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the first implantable defibrillator that avoids placing electrodes in or around the heart. Two large prospective studies (IDE [S-ICD System IDE Clinical Investigation] and EFFORTLESS [Boston Scientific Post Market S-ICD Registry]) have reported 6-month to 1-year data on the S-ICD. OBJECTIVES The objective of this study was to evaluate the safety and efficacy of the S-ICD in a large diverse population. METHODS Data from the IDE and EFFORTLESS studies were pooled. Shocks were independently adjudicated, and complications were measured with a standardized classification scheme. Enrollment date quartiles were used to assess event rates over time. RESULTS Eight hundred eighty-two patients who underwent implantation were followed for 651±345 days. Spontaneous ventricular tachyarrhythmia (VT)/ventricular fibrillation (VF) events (n=111) were treated in 59 patients; 100 (90.1%) events were terminated with 1 shock, and 109 events (98.2%) were terminated within the 5 available shocks. The estimated 3-year inappropriate shock rate was 13.1%. Estimated 3-year, all-cause mortality was 4.7% (95% confidence interval: 0.9% to 8.5%), with 26 deaths (2.9%). Device-related complications occurred in 11.1% of patients at 3 years. There were no electrode failures, and no S-ICD-related endocarditis or bacteremia occurred. Three devices (0.3%) were replaced for right ventricular pacing. The 6-month complication rate decreased by quartile of enrollment (Q1: 8.9%; Q4: 5.5%), and there was a trend toward a reduction in inappropriate shocks (Q1: 6.9% Q4: 4.5%). CONCLUSIONS The S-ICD demonstrated high efficacy for VT/VF. Complications and inappropriate shock rates were reduced consistently with strategic programming and as operator experience increased. These data provide further evidence for the safety and efficacy of the S-ICD. (Boston Scientific Post Market S-ICD Registry [EFFORTLESS]; NCT01085435; S-ICD® System IDE Clinical Study; NCT01064076).

[1]  A. Go,et al.  Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. , 2013, JAMA.

[2]  A. Wilde,et al.  Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. , 2014, Heart rhythm.

[3]  J. Pogue,et al.  Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE) , 2015, The Lancet.

[4]  P. Heidenreich,et al.  Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation , 2012, Circulation.

[5]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[6]  C. Israel,et al.  Electrical Storm in Patients with an Implanted Defibrillator: A Matter of Definition , 2007, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[7]  Michael O. Sweeney,et al.  Prospective Randomized Multicenter Trial of Empirical Antitachycardia Pacing Versus Shocks for Spontaneous Rapid Ventricular Tachycardia in Patients With Implantable Cardioverter-Defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial Results , 2004, Circulation.

[8]  Wojciech Zareba,et al.  Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.

[9]  A. Moss,et al.  Clinical Impact, Safety, and Efficacy of Single‐ versus Dual‐Coil ICD Leads in MADIT‐CRT , 2013, Journal of cardiovascular electrophysiology.

[10]  P. Lambiase,et al.  Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.

[11]  Martin J Schalij,et al.  Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. , 2011, Journal of the American College of Cardiology.

[12]  M. Gold,et al.  Head‐To‐Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study , 2012, Journal of cardiovascular electrophysiology.

[13]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[14]  M. Gold,et al.  Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. , 2013, Circulation. Arrhythmia and electrophysiology.

[15]  Nora Toma,et al.  An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, Maedica.

[16]  A. Wilde,et al.  Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. , 2013, Heart rhythm.

[17]  M. Gold,et al.  Efficacy and Temporal Stability of Reduced Safety Margins for Ventricular Defibrillation: Primary Results From the Low Energy Safety Study (LESS) , 2002, Circulation.

[18]  D. Hayes,et al.  Impact of shock energy and ventricular rhythm on the success of first shock therapy: the ALTITUDE first shock study. , 2013, Heart rhythm.

[19]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[20]  Alexander H Maass,et al.  An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, The New England journal of medicine.

[21]  Mark Kremers,et al.  Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator , 2013, Circulation.

[22]  L. Jordaens,et al.  The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. , 2012, Journal of the American College of Cardiology.

[23]  M. Gold,et al.  Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. , 2014, Heart rhythm.

[24]  A. Russo,et al.  The Dilemma of ICD Implant Testing , 2007, Pacing and clinical electrophysiology : PACE.